Loading…
Employees: 660
Size InMode (INMD) is a United States Health Care company (Medical Specialties) with a market value of $767M, the 2423rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.33 on 6 Nov 2026.
Performance Over six months the shares fell 4.5%, against -9.0% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 6.7% over the last twelve months (peer median +13.0%); the operating margin is 18.5% (peer median 11.2%).
Valuation It trades at 10.1× forward earnings against a peer median of 20.5× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 26.5 points above its cost of capital (14.7% WACC).
Short interest Short interest is 3.9% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $375M | $370M | $395M | $492M | $454M |
| Revenue growth | — | -6% | -20% | +8% | — |
| Gross profit | $287M | $291M | $317M | $411M | $381M |
| EBITDA | $69.9M | $86.1M | $113M | $196M | $199M |
| Net income | $77.5M | $93.8M | $181M | $198M | $162M |
| Free cash flow | $88.4M | $84.3M | $132M | $176M | $180M |
| Capital expenditure | $1.12M | $972,000 | $669,000 | $705,000 | $1.57M |
| Total debt | $4.45M | $8.23M | $7.82M | $9.02M | $4.96M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | -3.6% | 9th lowest of 21 |
| 6-month return | -4.5% | -9.0% | 9th highest of 21 |
| Distance from 52-week high | -20.0% | -23.9% | 10th highest of 21 |
| Revenue growth (TTM) | -6.7% | +13.0% | 2nd lowest of 21 |
| Operating margin | 18.5% | 11.2% | 5th highest of 21 |
| Forward P/E | 10.1× | 20.5× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -10.5% | 10.1% | least demanding of 15 |
| Growth delivered (Del g) | +12.4% | +14.9% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -22.9 pp | -6.2 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +26.5 pp | +0.3 pp | 3rd highest of 21 |
| EV / EBITDA | 3.9× | 13.3× | cheapest of 9 |
| Net debt / EBITDA | -7.1× | 0.6× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |